Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury
Phase 4
- Conditions
- Burns
- Registration Number
- NCT01012648
- Lead Sponsor
- University of Zurich
- Brief Summary
RCT colloids versus cristalloids only in severe burn victims.
* Trial with medicinal product
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Reduced amount of fluids given 3 days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie HES 130/0.4's efficacy in fluid resuscitation for severe burn injuries?
How does HES 130/0.4 compare to Ringer's lactate in managing hypovolemia in severe burn patients?
Which biomarkers predict optimal response to HES 130/0.4-based resuscitation in severe burn cases?
What are the potential coagulopathy risks and management strategies for HES 130/0.4 in burn resuscitation?
What alternative colloids or combination therapies are being evaluated alongside HES 130/0.4 for severe burns?
Trial Locations
- Locations (1)
Surgical ICU
🇨🇭Zurich, Switzerland
Surgical ICU🇨🇭Zurich, SwitzerlandMarkus Béchir, M.D.Principal Investigator